ArticleKidney international reports2025
Combination Cyclophosphamide and Rituximab to Minimize Glucocorticoid Use in Antineutrophil Cytoplasm Antibody-Associated Vasculitis.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucocorticoid reduction in Glomerular Diseases.Kidney international reports · 2026Review
- Primary central nervous system vasculitis: an update.Journal of neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The optimal duration of immunosuppressive therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is uncertain. Glucocorticoids are a mainstay of treatment but are associated with significant morbidity. Here, we describe outcomes of a cohort of patients treated with combination cyclophosphamide and rituximab induction alongside a rapidly tapering oral-only glucocorticoid regimen. Methods: In this retrospective, observational, cohort study, we identified patients presenting with AAV between 2011 and 2023 treated with combination cyclophosphamide and rituximab induction therapy. We analyzed biochemical, histologic, and outcome data, including time-to-remission and relapse rate. A subgroup analysis compared outcomes based on glucocorticoid duration. Results: A total of 112 patients with active AAV treated with combination cyclophosphamide and rituximab were identified (median age: 67 years; 85% kidney involvement; baseline estimated glomerular filtration rate [eGFR] 24 ml/min per 1.73 m Conclusion: Early withdrawal of oral glucocorticoid therapy in patients with severe AAV treated with combination cyclophosphamide and rituximab induction immunosuppression is safe and effective and may reduce morbidity, in particular serious infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.